FindTrial
Sign In

A clinical study on expanding donor pool and improving recipients' life quality and long-term survival: A three years study of donor-specific antibody monitoring and treatment after organ transplantation

A clinical study on expanding donor pool and improving recipients' life quality and long-term survival: A three years study of donor-specific antibody monitoring and treatment after organ transplantation

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OCH-13003352
Enrollment
Unknown
Registered
2013-05-03
Start date
2013-06-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Organ Transplantation

Interventions

HLA pre-sensitazation:HLA antibody monitoring
non HLA pre-sensitazation:HLA antibody monitoring
DSA positive:antibody treatment

Sponsors

Institute of Organ Transplantation, Tongji Hospital, Wuhan, Hubei
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. agree to participate in this study and give informed consent; 2. aged 18-65 years old, both male and female; 3. receive a liver or kidney transplant from a related-living donor or donor after cardiac death.

Exclusion criteria

Exclusion criteria: 1. ABO imcompatible transplantation; 2. transplantation from a deceased donor; 3. fail to complete the related examinations; 4. other situations that should be excluded into this study.

Design outcomes

Primary

MeasureTime frame
panel reactive antibodies;donor specific antibody;serum creatinine;proteinuria;graft biopsy pathology;Flow crossmatch;HLA matching;HLA-I antibody;HLA-II antibody;C4d deposition;acute rejection;—

Countries

China

Contacts

Public ContactChen Xiaoping
qgyzlc@tjh.tjmu.edu.cn+86 027-83665283

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026